FOFirat Omar

Firat Omar

*This is an algorithmically generated author record based on publicly available information.

Firat Omar has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Relationship Between C-Reaktif Protein/Albumin Ratio and Disease Activity in Axial Spondyloarthritis

    by Nurdan Oruçoğlu, Mustafa Erkut Önder, Fırat Omar

    Amaç: C-reaktif protein/albümin oranı (CAO) yakın zamanda yeni bir inflamatuar biyobelirteç olarak tanımlanmış ve inflamasyonun belirlenmesinde birçok hastalıkta potansiyel rolü ortaya konulmuştur. Bu çalışma, aksiyel spondiloartritte (axSpA) hastalık aktivitesinin belirlenmesinde CAO’nun rolünü araştırmayı amaçlamaktadır. Gereç ve Yöntem: Bu çalışma retrospektif vaka-kontrol çalışmasıdır. Toplam 128 hasta ve 111 yaş-cinsiyet uyumlu sağlıklı kontrol çalışmaya dahil edilmiştir. Serum albumin, C-reaktif protein (CRP), eritrosit sedimantasyon hızı (ESH) kaydedildi. CAO, serum CRP/Albumin şeklinde hesaplanmıştır. Hastalık aktivitesini belirlemek için Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI) ve Ankilozan Spondilit Hastalık Aktivite Skoru-CRP (ASDAS-CRP) skorları kullanıldı. Hastalar ASDAS-CRP skoruna göre iki alt gruba ayrıldı: ≥1,3 aktif hastalık, <1,3 inaktif hastalık olarak sınıflandı. Ayrıca axSpA hastaları radyografik ve non-radyografik hastalık olarak da alt gruba ayrıldı. Bulgular: CAO, axSpA hastalarında sağlıklı kontrollerinden anlamlı şekilde daha yüksekti (Sırasıyla 1,42 (0,91-4,49) ve 0,46 (0,25-0,95), p<0,001). Aktif hastalığı olanlarda da inaktif hastalığa sahip olanlara göre CAO anlamlı derecede daha yüksek bulundu (sırasıyla 4,61 (2,04-6,87) ve 0,977 (0,75-1,52), p < 0,001). CAO, CRP, ESH, BASDAI ve ASDAS-CRP ile anlamlı ölçüde korelasyon göstermekteydi (Sırasıyla r=0,996, p<0,001; r=0,471, p<0,001; r=0,779, p<0,001, r=0,842, p<0,001). CAO’nun aktif hastalığı inaktif hastalıktan ayırt etme gücü için eğri altında kalan alan (EAA) 0,795 (95% güven aralığı (CI) 0.714-0.861; p<0.001) idi. Sonuç: CAO, axSpA’da hastalık aktivitesi ile iyi derecede korelasyon göstermektedir. AxSpA’nın tanı ve takibinde inflamasyonun potansiyel bir göstergesi olarak kullanılabilecek, yararlı bir biyobelirteç olabilir. Objective: The C-reactive protein/albumin ratio (CAR) has recently emerged as a novel inflammatory biomarker, indicating its potential role in determining inflammation in various disorders. This study aims to investigate the role of CAO in determining disease activity in axial spondyloarthritis (axSpA). Materials and Methods: This study is a retrospective case-control study. A total of 128 patients with axSpA and 111 age-gender-matched healthy controls were included in the study. Serum albumin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were recorded. CAR was calculated as serum CRP/Albumin. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score-CRP (ASDAS-CRP) scores were used to determine disease activity. Patients were divided into two subgroups based on the ASDAS-CRP score: ≥1.3 was considered active disease, and <1.3 was considered an inactive disease. Additionally, axSpA patients were also subdivided into radiographic and non-radiographic disease groups. Results: CAR was significantly higher in axSpA patients compared to healthy controls (1.42 (0.91-4.49) and 0.46 (0.25-0.95), p<0.001, respectively). Similarly, CAO was found to be significantly higher in patients with active disease compared to those with inactive disease (4.61 (2.04-6.87) and 0.977 (0.75-1.52), p<0.001, respectively). CAR showed a significant correlation with CRP, ESR, BASDAI, and ASDAS-CRP (r=0.996, p<0.001; r=0.471, p<0.001; r=0.779, p<0.001, r=0.842, p<0.001, respectively). The area under the curve (AUC) for distinguishing active from inactive disease using CAR was 0.795 (95% confidence interval (CI) 0.714-0.861; P<0.001). The optimal cut-off value for CAR was 1.51, with a sensitivity of 78.6% and specificity of 75%. Conclusion: CAr correlates highly with disease activity in axSpA. It can potentially be a useful biomarker for determining and monitoring inflammation in axSpA.

  • Open Access

    C-Reactive Protein-to-Albumin Ratio: A Novel Inflammatory Marker and Disease Activity Sign in Early Rheumatoid Arthritis

    by Mustafa Erkut Onder, Nurdan Orucoglu, Firat Omar, Abdullah Canataroglu

    Objective A novel inflammation-based score, C-reactive protein (CRP)-to-albumin ratio (CAR), has been shown to have an association with the inflammatory status in several diseases. We aimed to analyse the association between CAR and disease activity in patients with early rheumatoid arthritis (RA) and to determine the cut-off value of CAR in early and established RA. Methods A total of 177 patients with RA and 111 age and gender-matched healthy controls were included in this study. Cases with a disease duration of less than 1 year were classified as early RA. Serum albumin, CRP, erythrocyte sedimentation rate (ESR), Disease Activity Score-28 (DAS-28-ESR), Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire (HAQ) scores were recorded. Results CAR was 2.44 (0.21–30.83) in the RA group and 0.45 (0.21–10.47) in the control group (p<0.001). Eighty-seven (49.15%) of the RA cases were classified as early RA. The analyses indicated that the ESR, CRP and CAR values were higher in patients with early RA than in those with established RA and controls. CAR was correlated with albumin, CRP, ESH, DAS-28 and HAQ scores in both early RA and established RA groups. The receiver operating characteristic curves revealed a CAR cut-off value of 2.67 (80% sensitivity and 85% specificity) and 1.63 (77% sensitivity and 72% specificity) for the prediction of early and established RA, respectively. Conclusion CAR, a formulated ratio, has been described as a predictor for disease activity in patients with early RA as well as in those with established RA. However, CAR has higher sensitivity and specificity for early RA than for established RA.